Sugi Predict

Sugi Predict / Compounds / SCHEMBL2065352

SCHEMBL2065352

SCHEMBL2065352

NC(=O)C1=CN([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(N)ncnc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)C=CC1.[NaH].[NaH]

nearest known ligand 0.98

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADH1A P07327 2/20 0.98
▸ LMNA P02545 1/20 0.77
▸ PMP22 Q01453 1/20 0.77
▸ TP53 P04637 1/20 0.77
▸ TSHR P16473 1/20 0.77
▸ ALOX12 P18054 1/20 0.77
▸ P2RY1 P47900 6/20 0.72
▸ P2RY2 P41231 2/20 0.72
▸ P2RX1 P51575 2/20 0.72
▸ P2RX3 P56373 2/20 0.72
▸ ALDH1A1 P00352 2/20 0.72
▸ SRC P12931 1/20 0.72
▸ P2RX4 Q99571 1/20 0.72
▸ P2RX2 Q9UBL9 1/20 0.72
▸ SMN1; SMN2 Q16637 1/20 0.72
▸ LDHA P00338 1/20 0.71
▸ LDHB P07195 1/20 0.71
▸ MACROD2 A1Z1Q3 1/20 0.68
▸ SIRT6 Q8N6T7 1/20 0.68
▸ MACROD1 Q9BQ69 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4121621 1.00 ADH1A (0.98) ADH1ALMNAPMP22TP53TSHR
SCHEMBL29350404 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL29740660 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL29548827 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL8187 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL1276381 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL29351291 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL20202727 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL8003782 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR
SCHEMBL8188 0.99 ADH1A (1.00) ADH1ALMNAPMP22TP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126235-A2 IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 Vanda Pharmaceuticals Inc. (US) 2023-02-08 — — EP claimed
CN-115335122-A Identification of compounds and their use in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 万带兰制药公司 2022-11-11 — — CN claimed
EP-3958926-A1 MULTIVASCULAR NETWORKS AND FUNCTIONAL INTRAVASCULAR TOPOLOGIES WITHIN BIOCOMPATIBLE HYDROGELS William Marsh Rice University (US) 2022-03-02 — — EP claimed
WO-2021195470-A2 IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 VANDA PHARMACEUTICALS INC. (US) 2021-09-30 — — WO claimed
WO-2020220046-A1 MULTIVASCULAR NETWORKS AND FUNCTIONAL INTRAVASCULAR TOPOLOGIES WITHIN BIOCOMPATIBLE HYDROGELS Volumetric Biotechnologies, Inc. (US) 2020-10-29 — — WO claimed
US-20200339925-A1 MULTIVASCULAR NETWORKS AND FUNCTIONAL INTRAVASCULAR TOPOLOGIES WITHIN BIOCOMPATIBLE HYDROGELS WILLIAM MARSH RICE UNIVERSITY 2020-10-29 — — US claimed
CN-122036829-A Crystal form of NADH disodium salt and preparation method thereof 风火轮(上海)生物科技有限公司 2026-05-15 — — CN disclosed
US-20250332079-A1 TOPICAL SUNSCREEN CONCEPT MATRIX SOLUTIONS 2025-10-30 — — US disclosed
US-12350356-B2 Topical sunscreen CONCEPT MATRIX SOLUTIONS 2025-07-08 — — US disclosed
US-20240207215-A1 MARC1 INHIBITORS FOR TREATMENT OF LIPID METABOLISM DISORDERS CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL (DE) 2024-06-27 — — US disclosed
CN-118159638-A Manifold, system and method for performing biological studies in flow 3D 系统有限公司 2024-06-07 — — CN disclosed
WO-2024100202-A1 METHOD FOR PRODUCING AN AQUEOUS SOLUTION WHICH CONTAINS GLYCERIN ANNIKKI GMBH (AT) 2024-05-16 — — WO disclosed
EP-4368720-A1 PROCESS FOR PRODUCING AQUEOUS SOLUTION CONTAINING GLYCERIN Annikki GmbH (AT) 2024-05-15 — — EP disclosed
EP-0202743-A1 Assay for salicylate and apparatus for performing same MediSense, Inc. (US) 1986-11-26 — — EP disclosed
US-4352881-A Method of measuring creatine kinase activity MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1982-10-05 — — US disclosed
US-4349625-A ALBUMIN USING ACYL-COENZYME A SYNTHETASE MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1982-09-14 — — US disclosed
EP-0019875-B1 METHOD FOR ASSAYING FATTY ACIDS MITSUBISHI KASEI CORPORATION (JP) 1982-07-07 — — EP disclosed
US-4328311-A USEFUL IN IMMUNOASSAY SYVA COMPANY (US) 1982-05-04 — — US disclosed
EP-0019875-A1 Method for assaying fatty acids MITSUBISHI KASEI CORPORATION (JP) 1980-12-10 — — EP disclosed
US-4220722-A ACYLATION, AMIDATION, SULFIDING SYVA COMPANY (US) 1980-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332079-A1 TOPICAL SUNSCREEN SUN2, CYP51A1, DSG1 ADH1A 2064/4885LMNA 2665/4885PMP22 2639/4885
US-20240207215-A1 MARC1 INHIBITORS FOR TREATMENT OF LIPID METABOLISM DISORDERS FABP1, CES1, IRS1 ADH1A 121/4885LMNA 1251/4885PMP22 2886/4885
US-12350356-B2 Topical sunscreen SUN2, CYP51A1, DSG1 ADH1A 2064/4885LMNA 2665/4885PMP22 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.